TUBITAK Destekli Projelerden Çıkan Yayınlar Topluluğu
Published January 1, 2017 | Version v1
Journal article Open

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Creators

  • 1. Univ Copenhagen, Danish Dementia Res Ctr, Rigshosp, Copenhagen, Denmark
  • 2. Karolinska Univ Hosp, Dept Geriatr Med, Huddinge, Sweden
  • 3. Univ Coimbra, CNC IBILI Ctr Neurosci & Cell Biol, CHUC Coimbra Univ Hosp, Neurochem Lab,Fac Med,CNC, Coimbra, Portugal
  • 4. Univ Antwerp, Inst Born Bunge, Reference Ctr Biol Markers Dementia BIODEM, Antwerp, Belgium
  • 5. Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
  • 6. Polish Acad Sci, Mossakowski Med Res Ctr, Dept Neurodegenerat Disorders, Warsaw, Poland
  • 7. IRCCS Fatebenefratelli, Brescia, Italy
  • 8. Maastricht Univ, Sch Mental Hlth & Neurosci, Alzheimer Ctr Limburg, Maastricht, Netherlands
  • 9. Univ Med Ctr Ljubljana, Dept Neurol, Ctr Cognit Impairments, Ljubljana, Slovenia
  • 10. Med Univ Bialystok, Dept Neurodegenerat Diagnost, Bialystok, Poland
  • 11. Karolinska Inst, Translat Alzheimer Neurobiol, Ctr Alzheimer Res, Dept NVS, Huddinge, Sweden
  • 12. Univ Ulm, Dept Neurol, Ulm, Germany

Description

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebiospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support 4 recommendation to use CSF ADbiomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD bioniarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Files

bib-7a0b5eef-bdb9-42b0-aab7-556545afc022.txt

Files (407 Bytes)

Name Size Download all
md5:6ba017ab38d7a5809d5fe4c663da7283
407 Bytes Preview Download